Denmark's Evaxion Q2 net loss narrows on lower expenses

Evaxion A/S

20/08/2026 12:40

Overview
Denmark vaccine developer posted Q2 net loss narrowed from last year on lower financial expenses
Company reported no revenue for Q2, consistent with clinical-stage operations
Cash at hand of $14 mln expected to fund operations into H2 2027

Outlook
Evaxion expects to present three-year clinical data for EVX-01 in October 2026
Company plans to submit regulatory filing for EVX-04 clinical testing before end-2026
Evaxion says cash runway sufficient to fund operations into second half of 2027

Result Drivers
LOWER FINANCIAL EXPENSES - Co said reduced derivative liability and related remeasurement lowered net financial expense vs last year
LOWER CAPITAL MARKET COSTS - Co attributed reduced net loss vs last year to lower capital market transaction costs
INCREASED R&D SPENDING - R&D expenses rose slightly vs last year as co progressed its pipeline according to plan

Company press release: ID:nGNXPgyZC

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$3.73 mln
 
Q2 Loss Per Share
 
$0.01
 
Q2 Operating Income
 
-$3.85 mln
 
Q2 Pretax Loss
 
$3.93 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Evaxion A/S is $10.00, about 217.5% above its August 19 closing price of $3.15

Reuters Recommended Reads
Aug 20 - Denmark's BioPorto Q2 revenue falls 8% on recall, divestment
Aug 20 - Denmark's Stenocare Q2 sales more than doubles on domestic demand
Aug 20 - Sweden's Mendus Q2 net loss narrows

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)